Browse Category

Earnings Reports News 10 January 2026

Broadcom stock jumps after Mizuho lifts target; CPI week sets up next test for AVGO

Broadcom stock jumps after Mizuho lifts target; CPI week sets up next test for AVGO

Broadcom shares jumped 3.7% to $344.97 Friday, lifting the PHLX Semiconductor Index to a record. Mizuho raised its price target on Broadcom to $480, citing “attractive valuations.” Cathie Wood’s ARK Invest bought 31,573 shares, while Broadcom’s legal chief sold 30,000 shares. The stock remains 17% below its 52-week high after a December warning on profit margins.
Netflix stock slips as Paramount challenges Warner deal; CPI and earnings are next

Netflix stock slips as Paramount challenges Warner deal; CPI and earnings are next

Paramount Skydance reaffirmed its $108.4 billion bid for Warner Bros. Discovery, topping Netflix’s $72 billion offer. Netflix shares fell 1.2% to $89.46. Netflix co-CEO Greg Peters received 207,420 shares as performance-based stock units vested. Investors await U.S. inflation data Jan. 13 and Netflix’s fourth-quarter earnings Jan. 20.
Lam Research stock jumps on Mizuho target hike as chip-tool rally sets up next earnings test

Lam Research stock jumps on Mizuho target hike as chip-tool rally sets up next earnings test

Lam Research shares surged 8.7% to $218.36 Friday after Mizuho raised its price target and the PHLX chip index hit a record. Heavy trading snapped a two-day slide for Lam, which will report earnings Jan. 28. Applied Materials and KLA also posted strong gains. Traders are watching next week’s U.S. inflation data and the Fed’s policy meeting for signals on rate cuts.
GSK stock: $50m Noetik deal and Jemperli royalty lawsuit sharpen focus on Feb 4 results

GSK stock: $50m Noetik deal and Jemperli royalty lawsuit sharpen focus on Feb 4 results

AnaptysBio filed a motion to dismiss part of GSK’s claim in a Delaware court dispute over royalties from cancer drug Jemperli. The court is expected to hear the motion by early March, with trial set for July. GSK ADRs closed up 0.3% at $50.39 in New York; London shares slipped 0.26% to 1,886 pence. Investors await GSK’s Jan. 13 conference appearance and Feb. 4 results.
Keppel Ltd stock: Feb. 5 results date is set — here’s what traders watch next

Keppel Ltd stock: Feb. 5 results date is set — here’s what traders watch next

Keppel Ltd will release its second-half and full-year 2025 results on Feb. 5, after three Keppel-sponsored REITs report from Jan. 30. Keppel shares closed Friday down 0.7% at S$10.47, trading near a 52-week high. About 2.06 million shares changed hands, with S$10.46 as support and S$10.56 as resistance. All financial releases will be made before market open, the company said.
South32 stock near a 2026 high as dividend dates land; traders eye Feb 12 results

South32 stock near a 2026 high as dividend dates land; traders eye Feb 12 results

South32 shares closed up 1.1% at A$3.85, just below their 2026 high, after the miner released its 2026 calendar and set Feb. 12 for half-year results. The company confirmed a March 5 ex-dividend date and flagged a $60 million cost for the Mozal smelter shutdown in Mozambique. The S&P/ASX 200 slipped 0.03% as Rio Tinto fell 6.2%. Glencore shares surged over 10% on takeover talks with Rio Tinto.
Johnson & Johnson stock: TrumpRx drug discounts win tariff waiver as earnings loom

Johnson & Johnson stock: TrumpRx drug discounts win tariff waiver as earnings loom

Johnson & Johnson reached a deal with the Trump administration to cut U.S. drug prices and won exemptions from tariffs on its pharmaceuticals. The company will sell medicines at discounted rates through TrumpRx.gov and announced two new U.S. manufacturing sites. J&J stock closed down 0.7% at $204.39. Terms of the agreement remain confidential.
P&G stock in focus after Crest toothpaste label change — what to watch before Jan. 22 earnings

P&G stock in focus after Crest toothpaste label change — what to watch before Jan. 22 earnings

Procter & Gamble will change Kid’s Crest toothpaste packaging after Texas officials said label artwork encouraged unsafe fluoride use by children. The rollout began Jan. 1 and must last five years. P&G shares closed up 0.24% at $141.87, then slipped 0.17% after hours. Investors await the Jan. 22 earnings call for updates on volumes, pricing, and regulatory scrutiny.
1 100 101 102 103 104 203

Stock Market Today

XRP price today slips near $1.42 as thin weekend liquidity keeps traders on edge

XRP price today slips near $1.42 as thin weekend liquidity keeps traders on edge

7 February 2026
XRP fell about 5% Saturday to $1.42, extending a 22% weekly drop as thin liquidity and macro jitters drove sharp swings. Bitcoin rebounded above $70,000 after a brief plunge, while ether surged 12%. Ripple outlined plans for an “Institutional DeFi” roadmap, including a new lending protocol and permissioned DEX. The Federal Reserve held rates steady last week, with officials signaling caution on inflation.
Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

7 February 2026
Home Depot shares rose 0.7% to $385.15 Friday, trading between $379.10 and $386.37. Investors await a delayed U.S. jobs report Wednesday and CPI data Friday, both postponed by a brief government shutdown. Home Depot reports fourth-quarter earnings Feb. 24. The Dow closed above 50,000 for the first time.
JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

7 February 2026
JPMorgan shares rose 3.95% to $322.40 Friday, outpacing other major banks as U.S. stocks rallied and the Dow closed above 50,000 for the first time. The bank recently completed a $3 billion subordinated notes offering. Investors are watching for delayed U.S. jobs data and inflation figures next week, ahead of JPMorgan’s Feb. 23 company update.
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

7 February 2026
AbbVie shares rose 2% to $223.43 Friday, capping a volatile week marked by earnings and drug sales scrutiny. Moody’s upgraded AbbVie’s credit rating to A2, citing strong performance in immunology and neuroscience. Investors remain focused on Skyrizi and Rinvoq growth amid rising competition and recent regulatory filings. Trading volume stayed below average, with the stock still 9% off its 52-week high.
Go toTop